Discordance of clinical symptoms and electrophysiologic findings in taxane plus platinum-induced neuropathy

International Journal of Gynecological Cancer

Volumn 17, Issue 2, 2007, Pages 394-397

  Pan, Y ^a   Kao, M S ^b  

^a SAINT LOUIS UNIVERSITY HOSPITAL   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carboplatin; Docetaxel; Nerve conduction study; Neuropathy; Paclitaxel

Indexed keywords

CARBOPLATIN; DOCETAXEL; PACLITAXEL;

ADULT; ARTICLE; CASE REPORT; DRUG SUBSTITUTION; ELECTROPHYSIOLOGY; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; MULTIPLE CYCLE TREATMENT; NERVE CONDUCTION; NEUROPATHY; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT DURATION;

ACTION POTENTIALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CARCINOMA, ENDOMETRIOID; FEMALE; HUMANS; MIDDLE AGED; NERVOUS SYSTEM DISEASES; NEURONS, AFFERENT; OVARIAN NEOPLASMS; PLATINUM; TAXOIDS;

EID: 33947248524     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00766.x     Document Type: Article

References (10)

1. Mayerhofer K, Bodner-Adler B, Bodner K, Leodolter S, Kainz C. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity. Anticancer Res 2000;20:4047-50.
2. Katsumata N Docetaxel: an alternative taxane in ovarian cancer. Br J Cancer 2003;89(Suppl. 3):S9-15.
3. Pfisterer J, du Bois A, Wagner U et al. Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group. Gynecol Oncol 2004;92:949-56.
4. Hsu Y, Sood AK, Sorosky JI. Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity. Am J Clin Oncol 2004;27:14-8.
5. Vasey PA, Jayson GC, Gordon A et al. Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96:1682-91.
6. England JD, Gronseth GS, Franklin G et al. Distal symmetrical polyneuropathy: a definition for clinical research. Report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005;64:199-207.
7. The ICON and AGO collaborators. Paclitaxel plus platinum-based chemotherapy vs conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361: 2099-106.
8. Manfredi JJ, Horwitz SB. Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther 1984;25:83-125.
9. New PZ, Jackson CE, Rinaldi D, Burris H, Barohn RJ. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 1996;46:108-11.
10. Argyriou AA, Polychronopoulos P, Iconomou G, Koutras A, Kalofonos HP, Chroni E. Paclitaxel plus carboplatin-induced peripheral neuropathy: a prospective clinical and electrophysiological study in patients suffering from solid malignancies. J Neurol 2005;252:1459-64.